{"id":"W4391689991","doi":"10.1007/s13555-023-01075-y","title":"Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; McMaster University; Dermatrials Research; Probity Medical Research; University of British Columbia; SKiN Health","funders":"Celgene; Pfizer; Eli Lilly and Company; Amgen","keywords":"Ixekizumab; Plaque psoriasis; Psoriasis; Medicine; Interleukin 17; Interleukin 23; Antagonist; Interleukin; Interleukin 1 receptor antagonist; Pharmacology; Internal medicine; Receptor antagonist; Dermatology; Secukinumab; Cytokine; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001441402,0.0002200207,0.0008312545,0.0002771045,0.0001400748,0.0002976362,0.0001142972,0.0002766346,0.0009962042],"category_scores_gemma":[0.001607365,0.0001441479,0.0006726633,0.0001947179,0.0001617277,0.0003725762,0.0002225398,0.0004957228,0.0001477021],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002163297,"about_ca_system_score_gemma":0.0001604691,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002282595,"about_ca_topic_score_gemma":0.000374854,"domain_scores_codex":[0.9994642,0.0002567209,0.00004850861,0.00008353049,0.00005725078,0.00008977834],"domain_scores_gemma":[0.9982852,0.0007661877,0.0004221657,0.0001094243,0.00008347302,0.0003336247],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4442995,0.00370252,0.4366392,0.0002693277,0.001236775,0.0002949325,0.0003047474,0.003530052,0.02871492,0.0001260019,0.0005628173,0.08031911],"study_design_scores_gemma":[0.005577154,0.1140389,0.8720533,0.00001810784,0.0006935894,0.0003051813,0.0001583965,0.003523845,0.002852584,0.0001244297,0.0006191144,0.00003542463],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9994102,0.0002381722,0.00006531228,0.000008834691,0.00000463066,0.0000257467,0.00003987065,0.000003648577,0.0002036476],"genre_scores_gemma":[0.9996119,0.00005193529,0.00008621901,0.0000149959,0.00001155897,0.0000257973,0.00008007279,0.000001213296,0.0001164417],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001441402,"threshold_uncertainty_score":0.007622957,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0174092830187321,"score_gpt":0.2538951513793576,"score_spread":0.2364858683606255,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}